31/05/2024  09:11:14 Var. +2.1400 Volume Denaro21:58:00 Lettera21:58:32 Capitalizzazione di mercato Dividend Y. Rapporto P/E
171.8600EUR +1.26% 0
Fatturato: 0.0000
-Quantità in denaro: - -Quantità in lettera: - 83.94 bill.EUR - -

Descrizione business

CSL is a global specialty biotherapeutics company that develops and delivers innovative biotherapies that save lives, and help people with life-threatening medical conditions live full lives. CSL has acquired a number of companies. They include: Aventis Behring, which is now known as global biotech leader CSL Behring, U.S. plasma collector Nabi, which helped to form the world's premier plasma collection company in CSL Plasma, the Novartis influenza vaccine business, now integrated and known as Seqirus, the world's second largest influenza vaccines company and Calimmune, a leader in gene-modification and cell delivery technology.
 

Consiglio di amministrazione & Consiglio di sorveglianza

CEO
Paul Perreault
Consiglio di amministrazione
Alan Wills, Bill Campbell, Bill Mezzanotte, Elizabeth Walker, Greg Boss, John Levy, Mark Hill, Paul McKenzie
Consiglio di sorveglianza
Dr. Brian McNamee, Abbas Hussain, Bruce Brook, Carolyn Hewson, Dr. Megan Clark, Fiona Mead, Marie McDonald, Pascal Soriot, Paul Perreault, Professor Andrew Cuthbertson
 

Dati aziendali

Name: CSL Ltd.
Indirizzo: Poplar Road 45,Parkville VIC 3052, Australia
Telefono: +61-3-9389-1911
Fax: +61-3-9389-1434
E-mail: -
Internet: www.csl.com.au/
Industria: Healthcare
Settore: Pharmaceutical Industry
Sub settore: Pharmaceuticals
Fine dell'anno finanziario: 30/06
Flottante libero: 42.01%
Data dell'IPO: 30/05/1994

Rapporti con gli investitori

Name: Mark Dehring
IR telefono: +61-3-9389-3407
IR Fax: -
IR e-mail: mark.dehring@csl.com.au